Skip to content
HomeBriefFor youTrackersTopicsCompaniesGlossaryNewsletterSecurityHealth & medicineFinance & marketsRoboticsModels & researchPolicy & regulationEnterprise & businessDeveloper tools
Health & medicine · Nov 18, 2026 · 3 min read

Isomorphic Labs raises $5 billion with no drug in a human: the largest private biotech round ever, $7.7 billion in twenty months, and what the money is actually buying

The DeepMind spinout has now raised more than most public biotechs are worth, on preclinical data it has not published. The bet is that an AI design engine changes the clock, and the first trial is the test.

Why it matters
FinanceNo valuation disclosed, no clinical data, partnership revenue capped at Lilly and Novartis milestones. The round prices the engine; the first IND filing is the first event that can reprice it either way.
ExecutivesIf you run a pharma partnership desk, your counterparty just stopped needing your money. Expect fewer out-licensing deals from Isomorphic and more co-development on its terms.
ML engineersThe claim is faster design-make-test cycles. The public evidence is structure prediction; binding affinity and toxicity prediction in real programmes remain unpublished. Ask for a prospective hit rate.

Isomorphic Labs announced on Tuesday an oversubscribed $5 billion Series C, co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor and Alphabet, which spun the company out of DeepMind in 2021, continuing with what the release calls a significant investment. Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund returned. BioSpace describes it as the largest fundraise in the history of the biotech industry. It follows a $600 million first external round in March 2025 and a $2.1 billion Series B led by Thrive in May, which puts external funding at about $7.7 billion in twenty months. The company disclosed no valuation; Bloomberg reported earlier this month that talks were at around $50 billion.

What the money is for

The release names four uses: maturing the IsoDDE drug design engine and the simulation models behind it, building a partner ecosystem, global AI-bioengineering infrastructure, and what it calls AI-first translational and clinical development infrastructure. The last item is the new one. Isomorphic has to date presented itself as a design company that hands molecules to partners; building its own clinical capability means it intends to take programmes into humans itself. The release says positive preclinical results in oncology and immunology set the stage for clinical entry, but names no candidate, target, indication or date. Demis Hassabis has said in interviews that the first trial could begin by the end of this year.

The existing partnerships are the only revenue on the table: Eli Lilly, with up to $1.7 billion in milestones, and Novartis, with up to $1.2 billion, both signed in January 2024, and Johnson & Johnson, which joined in January on undisclosed terms. Milestone payments arrive when programmes advance, which is to say the partnerships pay out on the same event the Series C is waiting for.

The market it sits in

Menlo Ventures' healthcare report, published Monday, estimates 2026 spending on AI drug discovery at $700 million, up from $30 million a year earlier, the fastest-growing category in a healthcare AI market the firm puts at $3.7 billion. That whole category's annual spend is a seventh of what Isomorphic raised in one round. The comparison makes the point: this is not a company selling into the drug-discovery software market, it is a company that intends to own drugs, and it is being valued as a pharmaceutical platform rather than as a vendor.

The counter-argument

Every AI drug-discovery company that reached the clinic before Isomorphic has learned that the bottleneck was never the design step. Phase 2 failure rates for AI-designed molecules have so far matched the industry average, because efficacy in humans depends on target biology that no structure model has changed. Isomorphic's published evidence remains the AlphaFold lineage, which predicts structure; its claims about binding, selectivity and toxicity prediction are internal. A $5 billion round for a company whose first human dose is still ahead of it is a statement about the investors' cost of capital at least as much as about the science. And the alternative use of that capital, forty $125 million Series A rounds in the same field, would have bought a great deal of diversification.

What to watch

An IND filing or a first-patient-dosed announcement before the end of December, which would convert Hassabis's statement into a dated programme and start the milestone clock with Lilly or Novartis. Any disclosure of the valuation, which determines whether the company is now worth more than the partners it designs for. Whether the new clinical infrastructure is built or bought; a CRO acquisition would be the fastest route. And the next Menlo-style spending survey: if the drug-discovery category is still measured in hundreds of millions while its leading company is measured in tens of billions, the gap is the risk.

Key terms in this story

  • Oversubscribed (IPO book) When investors have placed orders for more shares than a company is offering in its initial public offering.
  • Network token (payments) A substitute card number issued by Visa, Mastercard or American Express for one transaction or merchant, so the real card details never reach the merchant or the software making the purchase.
All 99 terms →
fundinghealthresearchGoogle
Written in our own words from the linked sources · updated 2026-11-18 · corrections: corrections@aibriefing.io

Get the brief in your inbox

One email every morning: the stories that mattered in AI, each with a one-line "why it matters" for your role. Free, no ads, unsubscribe any time.

Published daily by AI Briefing. We never share your address.
Like this? Get tomorrow's brief by email, free.